Welcome New Members!

bioagilytix labs logoBioAgilytix Labs is a bioanalytical lab specializing in large-molecule bioanalysis, offering PK, immunogenicity, biomarkers, and cell-based assays supporting the development and release testing of biologics and small molecule therapeutics. Our services support drug discovery, pre-clinical & clinical development, and manufacturing; and they include assay development, validation, and sample analysis under non-GLP, spirit-of-GLP, and GLP, as well as product release testing under GMP. Link

decipheraDeciphera Pharmaceuticals, LLC is a clinical-stage biotechnology company developing improved kinase inhibitor treatments for cancer. Deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. With business and development operations based in Cambridge, MA, and dedicated research capabilities in Lawrence, KS, Deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers. Link

new health sciences logoNew Health Sciences, Inc. is developing Hemanext, a technology designed to improve the safety and efficacy of transfusion therapy through novel storage methods potentially extending the shelf life of refrigerated red blood cells while improving their quality across the storage cycle. Link

sanford rose associates logoSanford Rose Associates – Toft Group is a life sciences focused executive search firm, committed to changing the future of medicine – one relationship at a time. Our customers include biotechnology, medical device, diagnostic, pharmaceutical & healthcare companies. We have offices in the 3 rapidly-growing biotech hubs: San Francisco, San Diego & Boston. We routinely recruit for Director-level through CEO and Board positions, and deliver high quality results according to committed and aggressive timelines. The 80%+ repeat & referral rate we hold today is a direct result of our proven executive search strategies, designed to identify higher quality talent faster than other executive search firms. The Toft Group is the #1 performing executive search firm within Sanford Rose Associates® International network of 55+ offices worldwide. Link

 

Top 5 News Stories – 7/21/14 – 7/25/14

Top 5 logo1) Broad Institute receives $650 million mental research gift – Boston Globe, July 22, 2014

The Broad Institute, a biomedical research juggernaut in Cambridge, has received the biggest gift worldwide for psychiatric research, a $650 million commitment that could help scientists unravel the genetic underpinnings of diseases such as schizophrenia and bipolar disorder and begin to develop better treatments. Link

2) Biogen Idec MS drug is approved by European regulators  Boston Globe, July 23, 2014

European regulators Wednesday gave Cambridge biotech Biogen Idec Inc. approval to sell a new kind of injectable drug to treat multiple sclerosis. The medicine, called Plegridy, treats adults with relapsing-remitting multiple sclerosis, the most common form of the neurodegenerative disease. An application to sell Plegridy in the United States is pending with the Food and Drug Administration and a decision is expected later this summer. Link

3) Beth Israel Deaconess Medical Center opens new cancer-research center – Boston Business Journal, July 24, 2014

The Institute for RNA Medicine, established under renowned cancer geneticist and Beth Israel Deaconess Cancer Center Director Pier Paolo Pandolfi, and co-founded by BIDMC Chairman of Pathology Jeffrey Saffitz and molecular biologist John Rinn, will look at non-coding RNA, or the pieces of genetic coding material that contain clues about health and disease. Link

4) Another week, another biotech IPO: Ocular Therapeutix – BetaBoston, July 25, 2014

Bedford’s Ocular Therapeutix has raised $65 million through an initial public offering of stock, the 13th Massachusetts biotech firm to go public this year. The company follows last week’s IPO of Sage Therapeutics, and pushes the state’s record of Massachusetts biotech IPOs in a year to a new level. Ocular, a developer of therapies for eye diseases and conditions, offered shares at $13, below its previous forecast of $14 to $16 a share. Link

5) Shire inks a $225M rare disease deal on the eve of life with AbbVie – Fierce Biotech, July 23, 2014

Shire has signed a $225 million agreement to brighten its future in rare diseases, bolstering a major selling point for AbbVie as the two prepare for a $54.7 billion merger. Under the deal with Calabasas, CA’s ArmaGen, Shire will hand over $15 million up front and up to $210 million more in equity investment and milestone payments to get its hands on a treatment for the rare Hunter syndrome. Link

 

 

MassBio & Fisher Scientific Summer Supplier Series Kicks Off This Week!

SSS 2013 Logo

MassBio and Fisher Scientific are bringing their annual vendor expo on the road again this year!  Fisher Scientific’s preferred suppliers and MassBio’s Primary Suppliers will showcase the latest technologies, equipment, supplies and services at four different locations throughout the Massachusetts area this summer and fall. Hope to see you there!

Dates & Locations:

July 24, 2014 11am – 1pm
Worcester Gateway Park, 60 Prescott St, Worcester, MA

August 12, 2014, 11am – 1pm
Cambridge Science Center- 245 First Street, Cambridge MA

August 28th, 2014, 11am – 1pm
One Kendall Square, Building 600/700, Cambridge MA

September 19th, 2014, 11am-1pm
500 Cummings Center, Room 221E, Beverly MA

No registration is required, just stop by during your lunch break and grab a slice of pizza!

 

fisher sci

Welcome New Members

better business logoBetter Business Globally, LLC (BBG) is a unique firm that prepares employees and their families for corporate relocation abroad with Cultural Transition Advantage (CTA™) training. CTA™ eases the psychosocial transition of relocation by helping individual and/ or parents focus on the positive, growth-enhancing variables of their life abroad. Work-family balance is a key factor in the success of relocating executives and their families abroad. Discover how CTA™ can increase the success of your company’s relocation and expansion. BBG consults both privately and through human resources with comprehensive services assisting in pre and post transfer preparation and cross cultural adaptation. Services range from individual consultation to group trainings. Link

Solid Ventures

Solid Ventures is a biotechnology company focused on finding a treatment for Duchenne Muscular Dystrophy. Link

Top 5 News Stories – 7/14/14 – 7/18/14

Top 5 logo1) AbbVie and Shire come to terms on a $55B union – FierceBiotech, July 18, 2014

After months of semi-clandestine courtship, AbbVie and Shire have settled on a price: For $54.7 billion in cash and stock, the U.S. drugmaker will absorb its Irish target, securing a pipeline of promising rare disease treatments and a new address that should slash its tax rate. Link

2) Roche and Merck KGaA team on a multicancer companion diagnostic test – FierceDiagnostics, July 14, 2014

Companion diagnostics deals are an unstoppable train, and once again, Roche’s Ventana Medical Systems is at the center of another new partnership in the space. Ventana said it will develop a companion diagnostic test with Germany’s Merck KGaA that can be used for many different cancer types. Link

3) FDA Revises Policies on Obtaining Informed Consent in Clinical Trials Regulatory Affairs Professionals Society (RAPS), July 15, 2014

As FDA explains in the draft guidance, Informed Consent Information Sheet, when most people think about the process of obtaining consent, they think of it as obtaining written consent from the subject to participate in a medical study. But FDA says this understanding—while technically correct—is not complete. Link

4) Seres Makes Push for First Drug, and IPO, of Microbiome Era – Xconomy, July 16, 2014

The first regulated therapy to emerge from the recent explosion of microbiome research is one step closer. And the company developing it, Seres Health, is stepping toward the first microbiome startup IPO. But what makes the update newsworthy, other than the growing body of clinical data, is that Seres is now planning a much larger trial by the end of the year. It will also apply to the Food and Drug Administration for special “breakthrough” status that would help speed up development and regulatory timelines for the product. Link

5) Massachusetts Life Sciences Firms Wary of Lower Device Costs Medical Product Outsourcing (MPO), July 14, 2014 

As the pressure to make health care more affordable mounts, Massachusetts biotech companies and medical device makers are warning that lower costs for consumers could be bad for business. Companies and investors in the life sciences cluster—a crucial part of the state’s economy—claim new restrictions on payments for drugs and other medical products will stifle innovation and harm patients. Link